Nuvio
Commercial- Indications
- Poultry gut health, Swine gut health
Company intelligence / Profile preview
MicroSintesis has developed a proprietary proteobiotic technology that uses bioactive peptides as quorum sensing inhibitors to maintain healthy gut microbiomes in livestock. Their lead product, Nuvio Poultry, has demonstrated positive return on investment by improving flock health and reducing reliance on traditional anti-infectives. The company’s approach does not alter the overall microbial composition but instead disrupts harmful bacterial communication to prevent disease states. Clinical results are focused on improved animal health outcomes rather than traditional pharmaceutical endpoints.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MicroSintesis.